Clinical study to investigate safety and efficacy on a combined use of rituximab and auto-gamma/delta T cell therapy for CD20-positive B-cell lymphoma.
Not Applicable
- Conditions
- CD20-positive B-cell lymphoma
- Registration Number
- JPRN-UMIN000003641
- Lead Sponsor
- Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Active enteritis; - Active autoimmune diseases; - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety : Adverse events
- Secondary Outcome Measures
Name Time Method Overall survival Event free survival Response of measurable lesion Immunological responses